Trade 180 Life Sciences Corp. - ATNF CFD
Add to favourite- Summary
- Historical Data
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 2.23 |
Open | 2.21 |
1-Year Change | 125.51% |
Day's Range | 2.15 - 2.33 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 26, 2024 | 2.29 | 0.08 | 3.62% | 2.21 | 2.33 | 2.15 |
Jul 25, 2024 | 2.22 | 0.06 | 2.78% | 2.16 | 2.31 | 2.09 |
Jul 24, 2024 | 2.16 | -0.05 | -2.26% | 2.21 | 2.30 | 2.10 |
Jul 23, 2024 | 2.23 | 0.05 | 2.29% | 2.18 | 2.39 | 2.15 |
Jul 22, 2024 | 2.18 | 0.10 | 4.81% | 2.08 | 2.27 | 1.96 |
Jul 19, 2024 | 2.12 | -0.12 | -5.36% | 2.24 | 2.25 | 2.09 |
Jul 18, 2024 | 2.35 | 0.07 | 3.07% | 2.28 | 2.47 | 2.20 |
Jul 17, 2024 | 2.28 | 0.06 | 2.70% | 2.22 | 2.58 | 2.22 |
Jul 16, 2024 | 2.27 | 0.28 | 14.07% | 1.99 | 2.38 | 1.93 |
Jul 15, 2024 | 2.01 | -0.03 | -1.47% | 2.04 | 2.13 | 1.96 |
Jul 12, 2024 | 2.07 | -0.21 | -9.21% | 2.28 | 2.31 | 1.91 |
Jul 11, 2024 | 2.26 | -0.04 | -1.74% | 2.30 | 2.61 | 2.19 |
Jul 10, 2024 | 2.30 | -0.68 | -22.82% | 2.98 | 3.22 | 2.16 |
Jul 9, 2024 | 2.88 | 1.22 | 73.49% | 1.66 | 4.74 | 1.66 |
Jul 8, 2024 | 1.54 | 0.00 | 0.00% | 1.54 | 1.54 | 1.53 |
Jul 5, 2024 | 1.49 | -0.01 | -0.67% | 1.50 | 1.51 | 1.47 |
Jul 3, 2024 | 1.58 | 0.04 | 2.60% | 1.54 | 1.58 | 1.51 |
Jul 2, 2024 | 1.58 | 0.06 | 3.95% | 1.52 | 1.58 | 1.48 |
Jul 1, 2024 | 1.48 | -0.03 | -1.99% | 1.51 | 1.51 | 1.47 |
Jun 28, 2024 | 1.58 | 0.14 | 9.72% | 1.44 | 1.66 | 1.43 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
180 Life Sciences Corp. Company profile
About 180 Life Sciences Corp
180 Life Sciences Corp. is a clinical stage biotechnology company. The Company is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and inflammatory diseases. The Company has three product development platforms each of which focused on different diseases, pains or medical conditions and target different factors, molecules or proteins, and has their own product candidates, including Anti-TNF, which focusing on fibrosis and anti-tumour necrosis factor (anti-TNF); SCAs focused on drugs, which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs); and α7nAChR focusing on alpha 7 nicotinic acetylcholine receptor (α7nAChR). It conducting clinical trials only for certain indications under the anti-TNF platform. Out of its three product development platforms, only the SCAs platform, involves products that are related to CBD.
Financial summary
BRIEF: For the nine months ended 30 September 2021, 180 Life Sciences Corp revenues was not reported. Net loss increased from $9M to $21.4M. Higher net loss reflects General and administrative increase of 58% to $8.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.90 to -$0.77.
Industry: | Bio Therapeutic Drugs |
3000 El Camino Real
Bldg 4, Ste 200
94306
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com